The company's financial stability is highly precarious, evidenced by a minimal $7.65 million cash position supporting a substantial $342 million annual revenue base.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Total Current Assets | 37.5M | 59.42M | 47.74M | 18.43M |
| Cash & Short-Term Investments | 7.65M | 6.72M | 2.49M | 2.17M |
| Cash Only | 7.65M | 6.72M | 2.49M | 2.17M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 14.97M | 32.39M | 27.25M | 739.57K |
| Days Sales Outstanding | 15.95 | 38.78 | 40.57 | 1.25 |
| Inventory | 9.17M | 12.69M | 8.2M | 8.12M |
| Days Inventory Outstanding | 11.35 | 17.41 | 15.71 | 18.19 |
| Other Current Assets | 0 | 88.07K | 159.9K | 0 |
| Total Non-Current Assets | 8.73M | 6.89M | 877.63K | 877.63K |
| Property, Plant & Equipment | 461.36K | 595.87K | 0 | 0 |
| Fixed Asset Turnover | 742.49x | 511.61x | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 500K | 500K |
| Other Non-Current Assets | 8.27M | 6.29M | 377.63K | 377.63K |
| Total Assets | 46.23M | 66.31M | 48.62M | 19.31M |
| Asset Turnover | 7.41x | 4.60x | 5.04x | 11.15x |
| Asset Growth % | -30.28% | 36.39% | 151.76% | - |
| Total Current Liabilities | 179.15M | 172M | 143.61M | 109.39M |
| Accounts Payable | 25.35M | 41.69M | 43.35M | 30.41M |
| Days Payables Outstanding | 31.38 | 57.18 | 83.12 | 68.14 |
| Short-Term Debt | 72.95M | 55.41M | 29.45M | 23.38M |
| Deferred Revenue (Current) | 1.76M | 1.24M | 2.73M | 1.46M |
| Other Current Liabilities | 2.08M | 0 | 0 | 0 |
| Current Ratio | 0.21x | 0.35x | 0.33x | 0.17x |
| Quick Ratio | 0.16x | 0.27x | 0.28x | 0.09x |
| Cash Conversion Cycle | -4.07 | -0.99 | -26.84 | -48.69 |
| Total Non-Current Liabilities | 1.96B | 1.86B | 1.8B | 1.69B |
| Long-Term Debt | 365.09M | 355.4M | 318.93M | 312.51M |
| Capital Lease Obligations | 1.67M | 1.22M | 11.44M | 2.94M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.6B | 1.5B | 1.47B | 1.37B |
| Total Liabilities | 2.14B | 2.03B | 1.95B | 1.8B |
| Total Debt | 441.1M | 413.29M | 361.24M | 341.26M |
| Net Debt | 433.45M | 406.58M | 358.76M | 339.09M |
| Debt / Equity | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -1.88x | -1.67x | -0.24x | -4.90x |
| Total Equity | -2.09B | -1.96B | -1.9B | -1.78B |
| Equity Growth % | -6.8% | -3.34% | -6.78% | - |
| Book Value per Share | -318.34 | -298.08 | -288.44 | -270.12 |
| Total Shareholders' Equity | -2.26B | -2.12B | -1.97B | -1.85B |
| Common Stock | 4.4K | 4.4K | 2.79K | 2.79K |
| Retained Earnings | -2.26B | -2.12B | -1.97B | -1.85B |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.23K | 0 | 0 | 0 |
| Minority Interest | 168.69M | 158.64M | 76.66M | 71.66M |
Imminent liquidity shortfall risk
As reported in recent financial disclosures, POM's balance sheet trajectory appears increasingly precarious, with a cash position of only $7.65 million supporting a $342 million revenue base, suggesting that the company's ability to sustain its current growth trajectory without external capital is severely limited.
The persistent gap between revenue expansion and deep net losses indicates that the company is failing to achieve the operating leverage necessary to stabilize its financial foundation. Investors should monitor whether the current trajectory leads to a forced capital raise, which would likely be highly dilutive given the company's current market valuation and negative profitability profile.
Based on the company's reported figures, the liquidity buffer of $7.65 million is exceptionally thin relative to its operational scale, indicating that the firm lacks a sufficient cushion to absorb even minor shocks or regulatory shifts within the Chinese digital healthcare market.
The current liquidity profile suggests that the company is operating with minimal margin for error, leaving it highly sensitive to any disruption in its cash conversion cycle. This lack of liquidity may force management to prioritize short-term cash preservation over long-term strategic investments, potentially hindering future competitive positioning.
According to the company's operational profile, the reliance on a first-party pharmaceutical model suggests that a significant portion of assets is likely tied up in inventory, which warrants further investigation into potential obsolescence risks given the competitive pricing environment in the Chinese market.
The asset mix appears heavily weighted toward working capital items rather than high-value intellectual property or infrastructure. This asset-heavy structure, combined with low gross margins, implies that the company's balance sheet is vulnerable to inventory write-downs if demand for specific chronic care medications shifts unexpectedly.
As indicated by the deep net margin of -41.85%, the company's balance sheet may be masking significant underlying liabilities or non-operating drags that are not immediately apparent in the headline figures, suggesting that the firm's true financial health is likely weaker than the reported assets imply.
The disconnect between revenue growth and bottom-line performance suggests that the company may be relying on unsustainable financing or deferred payment terms to manage its operations. Analysts should be wary of potential off-balance-sheet obligations or contingent liabilities that could further impair the company's already strained liquidity position.
Quick answers to the most common questions about buying POM stock.
As of 2024, POMDOCTOR Ltd (POM) had total assets of $46.2M including $37.5M in current assets.
POMDOCTOR Ltd (POM) carries total debt of $441.1M, offset by $7.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
POMDOCTOR Ltd (POM) has total shareholders' equity (book value) of $-2263.4M ($-318.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.
POMDOCTOR Ltd (POM) reported a current ratio of 0.21x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.